Neisseria meningitidis antigens and compositions

Abstract

The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

1 . (canceled) 
     
     
         2 . A protein comprising (i) a fragment of at least seven consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920, or (ii) an amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         3 . The protein of  claim 2  comprising the fragment, wherein the fragment comprises at least ten consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         4 . The protein of  claim 3 , wherein the fragment comprises at least fourteen consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         5 . The protein of  claim 3 , wherein the fragment comprises at least twenty consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         6 . The protein of  claim 2  comprising the amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         7 . The protein of  claim 6 , wherein the amino acid sequence has at least 85% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         8 . A composition comprising the protein of  claim 2  and a pharmaceutically acceptable excipient. 
     
     
         9 . The composition of  claim 8 , further comprising an adjuvant. 
     
     
         10 . The composition of  claim 9 , wherein the adjuvant is an aluminum salt adjuvant. 
     
     
         11 . The composition of  claim 10 , wherein the aluminum salt adjuvant comprises aluminum hydroxide. 
     
     
         12 . The composition of  claim 9 , wherein the protein comprises the fragment and the fragment comprises at least ten consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         13 . The composition of  claim 12 , wherein the fragment comprises at least fourteen consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         14 . The composition of  claim 12 , wherein the fragment comprises at least twenty consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         15 . The composition of  claim 9 , wherein the protein comprises the amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         16 . The composition of  claim 15 , wherein the amino acid sequence has at least 85% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 
     
     
         17 . A method of inducing an immune response in a subject comprising administering the composition of  claim 9  to the subject.